14th January 2021 – (Hong Kong) One of the three COVID-19 vaccines purchased by the Hong Kong government is a vaccine produced by Sinovac in China. The later test results released by the Butantan Institute in Sao Paulo State recently showed that the overall effective rate was only 50.38%, slightly above the 50% approved standard threshold by World Health Organisation.
William Chui, a registered pharmacist and the President of The Society of Hospital Pharmacists of Hong Kong said on a radio program this morning (14th) that the elderly have poor immune systems and that the effectiveness of vaccination may be less than 50%. It is recommended that elderly in hospitals should avoid Sinovac vaccination. Chui explained that 95% of the people who received the Sinovac vaccine had the highest protection rate of only 62%.
Taking into account that the elderly and people with weakened immune systems will be less effective, he thinks that it is better for the young people to receive vaccination from Sinovac instead. He also pointed out that it is believed that the vaccine developed by Pfizer and BioNTech is the fastest to arrive in Hong Kong. The data shows that the vaccine is 95% effective for the elderly. He believes that even if the vaccine faces challenges in storage, the elderly should be considered as the priority group for vaccination. He also recommended the authorities consider Sinopharm Vaccine.
Respiratory system specialist Leung Chi-chiu said that if the high-risk group has only mild symptoms after vaccination, the pressure on the medical system can already be relieved. At this important juncture of prevention and control, any vaccine that is safe can help to reduce the medical burden.